Celsion Corporation Regains Compliance With NASDAQ Listing Requirements (CLSN)

Celsion Corporation CLSN, a leading oncology drug development company, today announced that it has received notification from the NASDAQ Listing Qualifications Department that it has regained compliance with the minimum Market Value of Listed Securities requirement for continued listing on the NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5550. Celsion received notice on April 6, 2011 that the Company was not in compliance with the Rule for continued listing on the NASDAQ Capital Market, which requires a listed company to maintain a minimum MVLS of $35 million. The letter from NASDAQ, received on May 10, 2011, stated that the Company's MVLS has been $35 million or greater for the last 10 consecutive business days (from April 26, 2011 to May 9, 2011). Accordingly, the Company has regained compliance with the Rule and this matter is now closed.